Form 4: MaxCyte Director Patrick J. Balthrop Acquires Shares and Stock Options

Director Patrick J. Balthrop acquired 21,367 shares of common stock and 40,701 stock options in MaxCyte, Inc. on June 11, 2024, as part of an annual equity grant.

Summary

• On June 11, 2024, Patrick J. Balthrop, a director of MaxCyte, Inc. (MXCT), acquired 21,367 shares of common stock in the form of restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of MaxCyte's common stock.
• Balthrop also acquired 40,701 stock options with an exercise price of $4.68.
• The stock options were granted on June 11, 2024, and are exercisable from June 10, 2034.
• These transactions were part of MaxCyte's Equity Grant Policy for non-employee directors.
• The shares underlying the RSU grant vest on June 11, 2025, contingent upon Balthrop's continued service as a director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The equity grant to a director aligns their interests with those of the shareholders.
• The vesting period encourages continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted stock units.

Industry Context

Equity grants to directors are a common practice in publicly traded companies to incentivize and align their interests with shareholders.

Comparison to Industry Standards

• Equity grants for non-employee directors are a standard practice across the biotechnology industry.
• Companies like Illumina, Thermo Fisher Scientific, and Danaher also provide equity compensation to their directors.
• The size and vesting schedules of these grants vary based on company size, performance, and industry norms.

Stakeholder Impact

• The equity grant aligns the director's interests with those of the shareholders, potentially leading to better decision-making.
• The vesting schedule encourages the director's continued service, benefiting the company and its stakeholders.

Key Dates